



French Healthcare

40th Annual J.P. Morgan
Health Care Conference

January 2022

A pro-business agenda making France more resilient and attractive for investors and international talents.

1) Solid fundamentals stimulating competitiveness and innovation

Since 2017, the French government has been committed to a program of flagship structural reforms to transform the economy, the lives of businesses and boost competitiveness through:



A new tax environment

Drastic reduction in corporate tax rate (from 33% to 25% by 2022) and production taxes (- €10 billion/year starting January 2021), flat tax of 30% on capital revenues, competitive taxation of R&D (corporate tax rate at 10% for revenues from IP, research tax credit equivalent to 30% of R&D expenditure).



A transformation of the French social model

Leading to greater flexibility and predictability (simplification of dismissals for economic reasons, facilitation of social dialogue), lower social security contributions on low salaries, adaptation of skills to the new needs of the economy (€15 billion Skills investment plan).



An acceleration of business setups

Simplification of administrative procedures for industrial setups (Acceleration and Simplification of Public Action Act), **127 ready-to-use sites** available for investors, removed obstacles to growth in businesses (Action Plan for Business Growth and Transformation Act).




An attractive ecosystem for international talents

Attractive personal tax regime for international talents (specific expatriation scheme for up to 8 years, up to 50% of the total remuneration exempted), dedicated procedures for entering and working in France (Talent passport, French Tech Visa Scheme), dedicated Business France's desk answering global mobility related questions from international tech talent (**Welcome to la French Tech**).

2) Unprecedented public investments for the recovery and to shape the France of 2030

A massive emergency economic plan of 470 billion euros, of which 300 billion euros in State-guaranteed loans, implemented from the onset of the global health crisis to protect the companies and their employees.



The "Relaunch France" economic stimulus plan (€100 billion, of which 70% will be spent by the end of 2021) to provide further support over the period 2020-2022 in strategic sectors, including healthcare, and with priority intervention to boost ecological transition.

A new investment plan "France 2030" unveiled by the President of France on October 12, 2021 to complete the cycle of reforms enabling France to transform itself and become more attractive. Backed by €30 billion, of which €3.5 billion will be disbursed by 2022, France 2030 is an ambitious continuum of public support to fast-track the emergence of breakthrough innovations and support their industrialization, especially in key sectors for tomorrow's healthcare.

3) Strong results with a recovery already achieved

THESE FAR-REACHING CHANGES AND MASSIVE PUBLIC SUPPORTS ALLOW FRANCE TODAY TO POST:



A renewed and maintained investor confidence, with France remaining the most attractive European country to foreign investors for the second year in a row in 2020. (EY, 2021)



A robust labor market, with an unemployment rate due to reach 7.6% by the end of 2021, the lowest since 2008 (INSEE), as well as 231,000 industrial jobs created or supported between September 2020 and August 2021.



A growth forecast of 6.3% in 2021 (versus 5% in the euro zone according to IMF).



A rediscovered optimism, with business profit shares higher than they were in 2018 (INSEE) and a default rate of businesses that needed a state-guaranteed loan since March 2020 less than 0.6% (Banque de France).

1) A constantly evolving living ecosystem



“ France has today made a choice. That of not being a country that sees healthcare innovations being designed and developed elsewhere, but of being a country that is taking its destiny in its own hands and is assuming the risk of innovating, inventing, manufacturing and selling tomorrow’s healthcare products and solutions worldwide. We have everything we need to succeed - the skills and the talent. And now we also have a plan and the resources. ”

Emmanuel Macron, French President

Market growth



OBJECTIVE

An ambition of **2.4% annual growth** set until 2024 for expenditure on drugs and healthcare products in the National Objective for Healthcare Expenditures.



ACTION

An increase of **€1 billion** for expenditures on drugs and medical devices announced by the Minister for Health in September 2021 and an extension of the criteria for reimbursement of medicinal products and medical devices, in addition to hospital rates, when the Improvement in “Actual Medical Benefit” is significant.

Rewarding investments in France



OBJECTIVE

To reinforce and better support investments in France and the EU (R&D and production) when fixing medicinal product prices through financial incentives.



ACTION

The bill on the funding of the social welfare for 2022 double financial support from €150 million to **€300 million**.

Major improvement in market access



OBJECTIVE

Achieving a market **access time** for medicines and medical devices **inferior to the European targets**.



ACTION

Immediate market access after the validation by the French National Health Authority (HAS) for all products assessed with an “Improvement in Actual Medical Benefit” (IAMB/ ASMR) ranked I to IV, with a two-year test period.

An improved early access scheme reform

France offers **one of the most open and efficient early-access schemes** for new therapeutics in Europe.

2 New access paths (early access and compassionate access) leading to a single set of access rules, reimbursement and faster granting.


Greater visibility and predictability for businesses and faster access for patients to the latest innovations, especially biotherapies.

1.1) A stimulus plan focused on **health**

Announced last June, the French government's **Healthcare Innovation 2030** devotes a significant portion of its investments to the health sector - €7 billion between now and 2030.

The overall ambition is to make France the leading European nation in terms of healthcare innovation and sovereignty, particularly in terms of biomedical research, clinical trials and, more generally, disruptive innovations in the health sector, through the development of biotherapy and support for

specialist healthcare startups, in order to achieve "a medicine that is more predictive, more preventive and more innovative."



1.2) **€7 billion** of State investment by 2030

	Transversal support for research : cluster policy, attractiveness of high level researchers, support for infrastructures.	→ €1 BILLION
	Transversal support for technology maturation and clinical trials .	→ €500 MILLION
	Acceleration strategies for biotherapies, digital health and emerging infectious diseases	→ €2 BILLION
	Support for industrial investment through calls for projects and an European IPCEI project.	→ €1.5 BILLION
	Support for emergence growth and industrialization of start-ups by Bpifrance	→ €2 BILLION

1.3) An **economically stable** sector

In 2019, the French pharmaceutical industry generated €60 billion. It is the 5th largest market worldwide for drugs.

The country has been so well placed for years partly due to a social security system that provides easy access to care for 67 million citizens.



France has very generous state funding for R&D, with tax breaks such as the **research tax credit, innovation tax credit and the**

innovative new companies status, but also innovation funding programs such as the Major Investment Plan.



France, **#1 country** for R&D subsidies within OECD countries thanks to the research tax credit, covering 30% of R&D expenses up to **€100 million**

Source: OECD

France is Europe's **most attractive country in terms of its research tax credit** (crédit d'impôt recherche – CIR) which is a tax-incentive scheme to support research that is open to companies of any size and from any sector: **30% of R&D expenses up to**

€100 million and 5% above, reimbursed or paid through corporate tax (highest R&D spending tax subsidy rate in OECD countries).

2) French HealthTech A European innovation leader

2.1) A priority for the Government

All these investments are designed to boost an already healthy ecosystem. In 2021, France has over 2,000 startups in the health sector employing 50,000 people.

In order to further encourage the marketing of innovations, the Health Plan 2030 provides for a series of adapted measures, namely - accelerating the launch of innovations on the market, facilitating the implementation of clinical trials and promoting joint projects between public and private entities.

Prioritizing the 3 areas that will make up the healthcare system of tomorrow:



Biotherapy and bioproduction



Digital health



Research into emerging infectious diseases and CBRN threats.




Oncology: #1 area investigated by French Biotech



Strong expertise in rare diseases

2.2) Prioritize investments to focus on future technologies



€650 M

To move to 5P medicine thanks to digital technology and to **create French champions.**



€750 M

To **prepare for pandemics** and have the means to respond to them in the country.



€1 BILLION

To strengthen our **biomedical research** capacity.



Simplification and speeding up of the **clinical trial authorization system.**



Develop our **methodological and operational expertise** in new types of clinical trials.

2.3) State of **the health sector** in France



2,000 startups
inc. 750 biotech; 1,100 medtech;
200 e-health businesses
50,000 jobs in 2021




+ 4,000 medical innovations being developed or already on the market
inc. 1,900 arising from biotechnology;
2,200 medical devices;



52% of Healthtech companies were created from academic or public research



400 digital health products



13 Nobel prizes



35,000 patents filed this year

Source: Panorama France Biotech 2020



The Health Innovation Plan 2030, beyond parametric reforms, affects all levers, transforms the healthcare ecosystem and facilitates the development, production and access to healthcare innovations in France. It draws lessons from the crisis by supporting the creation of a solid and innovative industrial base in the sector of drugs and medical devices to meet the healthcare challenges of tomorrow.

Agnès Pannier-Runacher
Minister Delegate to the Minister of the Economy, Finance and Recovery, in Charge of Industry

3) An international development strategy

By organizing meetings like the Health Tech innovation days in Paris last October, France is **facilitating exchanges between businesses and investors**.



“My mission consists mainly in identifying French talents based abroad or internationally and encouraging them to participate in our medical innovation ecosystem, whether in biotech, medtech or e-health.”
 Dr Rafaèle Tordjman


+155
 Healthcare companies selected


+300
 International investors


+15
 Pharmaceutical & industrial groups


20
 Conferences with 80 experts


1,300
 Networking events and private meetings

3.1) A strong presence outside France

France has implemented a number of measures to increase its visibility among investors and talents.

To make France the leading innovative nation in healthcare in Europe, the French biotech ecosystem has nominated a special envoy, Rafaèle Tordjman, Head of the Venture Capital Fund Jeito Capital.

3.2) French Health Tech, a constant presence on the international scene



With the support of Business France and French Healthcare, French businesses ensure a presence **at all global events**. From Dubai to Dusseldorf, French Health Tech is making itself known.

At the J.P. Morgan conference, no less than **30 French businesses** will present their projects.

3.3) A rising attractiveness for foreign investors



€7.3 billion
invested in R&D in 2020



€2.0 billion
invested in the French
manufacturing base in 2020



Almost 500
healthcare investment
projects identified since 2015.




Healthcare: 18%
of total investment by foreign
businesses in R&D centers in France.



Pharma/Medtech: 40%
increase in total investment by foreign
companies in 2020 versus 2019.

FRANCE IS THE MOST ATTRACTIVE COUNTRY IN EUROPE FOR FDI



4) Strong recovery after the COVID crisis


4.1) A sector that continues to expand

During the Covid crisis, no less than 100 French innovations have been launched to help in the fight against the pandemic. A momentum that has been maintained, as the number of projects continues to grow. The healthcare industry has seen 58 implementation projects compared to only 26 in 2019.

Although this trend is apparent in all European countries, France ranks 1st in this sector. France is also number one for investments in medical and surgical equipment, accounting for 40% of European projects in 2020.


4.2) The pharmaceutical sector expanding due to COVID

NUMBER OF FOREIGN INVESTMENT PROJECTS IN THE PHARMACEUTICAL SECTOR




4.3) Businesses continue to **innovate** to exit the pandemic

On November 26, the Government unveiled the 25 new winning projects of the “Capacity Building” call for expressions of interest to strengthen French production capabilities in the fight against COVID-19.











Source: SGPI - Gouvernement













Source: Business France






FRENCH HEALTHCARE DELEGATION AT THE 40TH ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE

 <p>www.4p-pharma.com</p>	<p>4P-PHARMA</p> <p>4P-Pharma aims to bring to patients curative solutions faster by:</p> <ul style="list-style-type: none"> - Building scientific approaches, linking innovative cellular target to disease biology - Leveraging on regulatory fast track to target large unmet medical needs - Risk mitigated path to market access through SPV incorporation and big pharma collaborations.
 <p>www.adocia.com</p>	<p>ADOCIA</p> <p>Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and metabolic diseases. In the diabetes field, Adocia’s portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring six clinical-stage products and several pre-clinical products. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use.</p>
 <p>www.algotx.com</p>	<p>ALGOTX</p> <p>AlgoTx develops novel drugs for complex pain where none is currently approved. The company was founded in 2018 and raised over 15 M€ to date to take its lead program ATX01 through formulation, pharmacology, pre-clinical toxicology and Phase I clinical development. ATX01 is a non-opioid topical treatment for the pain of Peripheral Neuropathy, entering Phase II in Chemotherapy-Induced Peripheral Neuropathy.</p>
 <p>www.alzprotect.com/en</p>	<p>ALZPROTECT</p> <p>ALZPROTECT is a French Biotech company developing therapeutic solutions for neurodegeneration. Its most advanced molecule, AZP2006, is actually in phase 2a for the treatment of Progressive Supranuclear Palsy (PSP). AZP2006 is a small molecule that modulates Progranulin levels which pleiotropic effects allow Neuroprotection and Neuroplasticity at late stages of neurodegeneration.</p>
 <p>www.apparius.fr</p>	<p>APPARIUS</p> <p>We execute M&A and fundraising for the best Tech entrepreneurs We pride ourselves on building long-term relationships with entrepreneurs from their Series A to their exit/IPO. We advise entrepreneurs and investors on the full spectrum of M&A transactions, including the sale of business, growth by acquisition and structured transactions.</p>





 <p>www.basecampvascular.com</p>	<p>BASECAMP VASCULAR</p> <p>Basecamp Vascular (BCV) is a French Medtech company developing a solution to enhance endovascular navigation. Its first-generation steerable mechatronic guidewire is designed to provide the practitioners with a direct access to cerebral vessels during mechanical thrombectomy for stroke treatment.</p>
 <p>www.biomunex.com</p>	<p>BIOMUNEX</p> <p>BIOMUNEX is discovering and developing differentiated immunotherapeutic approaches based on data driven biology, to address the unmet medical needs in oncology. Biomunex has created and developed a next-generation and robust Bispecific antibody technology platform, BiXAb®, thanks to a proprietary in silico modelling approach. The BiXAb® platform has been externally validated by out-licensing and collaboration deals with Sanofi and Onward Therapeutics signed in 2019 and 2021.</p>
 <p>www.biophytis.com/en</p>	<p>BIOPHYTIS</p> <p>BIOPHYTIS is a French clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases (lead development program is Sarcopenia, Biophytis is on track to initiate a Ph3 program), including severe respiratory failure in patients suffering from COVID-19 (Ph2/3 being completed with EUA targeted 2022).</p>
 <p>www.brenus-pharma.com</p>	<p>BRENUS PHARMA</p> <p>BRENUS PHARMA develops a discovery platform, scalable to generate the next generation of immunotherapies to treat solid tumours rare or frequent, thanks to our industry experience. An experienced team backed by Top KOL in vaccines in EU or US has conducted very positive in vitro and animal models of colorectal cancer (CRC) for its lead candidate STC-1010 to enter Phase 1/2 trial by end 2022 in EU and US in 1st line mCRC in combination with SOC including check point inhibitors.</p>
 <p>www.calixar.com</p>	<p>CALIXAR</p> <p>CALIXAR is a biotechnology company developing new approaches to isolate full-length and native membrane therapeutic targets with the highest purity levels. The company produces its own pipeline of medically relevant targets and uses its technology platform for other companies that need to identify, extract and purify membrane proteins (GPCRs, ion channels, receptors, transporters and viral targets).</p>

 <p>www.crossject.com/en</p>	<p>CROSSJECT</p> <p>CROSSJECT develops and will commercialize through partners a portfolio of rescue treatments, based on its needle-free technology, for emergency situations such as epileptic seizures, anaphylactic shock, opioid overdoses and severe asthma attacks. Crossject's ZENEO® needle-free auto-injector enables the simple and intuitive IntraMuscular or SubCutaneous self-administration of prefilled injectable drugs in less than a tenth of a second, in only two steps (open, push on injection site). The device has been tested through several Human Factors and clinical studies.</p>
 <p>www.deinove.com/en</p>	<p>DEINOVE</p> <p>DEINOVE is an industrial biotechnology company fully committed to the discovery of new antimicrobials to address the global health challenge of antimicrobial resistance. DEINOVE has built an R&D platform, the first of its kind in France and outstanding worldwide, to discover, characterize and produce new antimicrobials derived from bacterial biodiversity.</p>
 <p>www.diacurate.com</p>	<p>DIACCURATE</p> <p>Pancreatic cancers, stomach cancers, triple-negative breast tumors, aggressive blood cancers, brain metastases, HIV... to beat incurable diseases, Diaccurate is exploring the new frontiers of oncology and immunology in search of daring novel therapeutic approaches able to save lives. Now in the clinic, the French biotech is currently developing three sole-in-class drug candidates.</p>
 <p>www.e-scopics.com</p>	<p>E-SCOPICS</p> <p>E-SCOPICS S.A.S is a MedTech company developing dematerialized ultrasound technologies, to enable ultra-light digital "echosopes". The company democratizes the use of Ultrasound with a first connected Software "APP" to evaluate some aspects of NASH using ultrasound-based tissue parametric imaging. E-SCOPICS dematerialized ultrasound system supports quantitative elastography methods that estimate liver fibrosis severity via tissue stiffness. Liver elastography has proven to be a reliable method for liver fibrosis assessment in several chronic liver diseases like viral hepatitis.</p>
 <p>www.genoskin.com</p>	<p>GENOSKIN</p> <p>GENOSKIN is a Partner Research Organization (PRO) with a unique expertise in skin & immunology that aims to disrupt drug development by changing the way to generate human data, enabling better, faster, safer drug development. Our proprietary ex vivo human skin platforms represent last-line screens, in laboratory conditions, prior to clinical evaluation. Our technologies only include natural human skin obtained from screenable patients cohort maintained in a living and functional state for several days.</p>

 <p>GENOPOLE www.genopole.com</p>	<p>GENOPOLE</p> <p>As France's leading biocluster, GENOPOLE is an incubator for cutting-edge scientific projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides an auspicious environment for scientists and entrepreneurs seeking to advance research and innovation.</p>
 <p>Grapheal https://www.grapheal.com</p>	<p>GRAPHEAL</p> <p>Grapheal is a Medtech producing connected biosensors coupled to mobile technologies. Grapheal brings connectivity to biosensing by designing embedded biosensors and wearables. Grapheal's devices aim to provide field diagnostics and remote patient monitoring solutions, focusing on pathogens detection and wound care.</p>
 <p>imescia www.imescia.com</p>	<p>IMESCIA</p> <p>Imescia is developing a new platform in oncology for delivering best in class molecules. Our technology promotes tumor accumulation of anti-cancer drugs and preferential release within the tumor microenvironment to improve anticancer drug efficacy while decreasing toxicity. We have a first candidate ready to enter nonclinical development and proof of concepts on several other anticancer drugs.</p>
 <p>inHEART www.inheart.fr</p>	<p>INHEART</p> <p>inHEART provides a digital twin of the patient's heart from pre-operative medical images that contains key information to better plan and guide cardiac interventions. Results have shown to reduce procedure time from 5+ hours to 2- hours by replacing complex and tedious intra-operative electrical measurements with pre-operative image analysis. Moreover, it increases its success rate from 60% to more than 75%. inHEART technology is CE marked and registered to the FDA. Provided as a cloud-based service in more than 50 centres across Europe and US, it has benefited to more than 3,000 patients.</p>
 <p>meccellis biotech http://www.meccellis.com</p>	<p>MECCELLIS</p> <p>Meccellis is a medtech company that specializes in the development of biological implants based on Acellular Dermal Matric (ADM). They developed a diversified offer for multiple surgical specialties. They are also at the forefront of healthcare technologies as they developed new surgical solutions (Xenopha®: ADM combined with proprietary biopolymer P4HB) for addressing complex and challenging surgical conditions.</p>

 <p>MyData-TRUST www.mydata-trust.com</p>	<p>MYDATA-TRUST</p> <p>MYDATA-TRUST specialises in worldwide Data Privacy Laws compliance for North American, European and Asian companies and is exclusively dedicated to the Life Sciences Sector. MyData-TRUST currently support more than 300 clients worldwide ranging from Biotech, Pharma to CROs, e-Health, Healthcare and Academic. They specialise in Clinical Data Privacy Laws worldwide in the US (HIPAA, CCPA), in the EU (GDPR, UK, Swiss, Ukraine), and other parts of the world (POPIA, Brazil, Israel, Russia, China, etc.).</p>
 <p>OLGRAM www.olgram.com</p>	<p>OLGRAM</p> <p>By using artificial intelligence and combining 2 fields (stem cells and infectious diseases), OLGRAM developed a new molecule that is able to target directly and specifically the dormant bacteria allowing the complete clearance of the infection and thus curing the patient and break the vicious circle of infectious chronicity. OLGRAM is now entering the regulatory phase and is looking for partnerships with pharmaceutical / Biotechnology companies and investors.</p>
 <p>oncodesign www.oncodesign.com</p>	<p>ONCODESIGN</p> <p>ONCODESIGN is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and has been listed on Euronext Growth Market since April 2014. Its mission is the discovery of effective therapies to fight cancer and other diseases without therapeutic solutions. Oncodesign has configured its organization to offer innovative services to its customers and to license its proprietary molecules. Oncodesign has 233 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA.</p>
 <p>PHAR NEXT https://pharnext.com/en</p>	<p>PHARNEXT</p> <p>Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A ('CMT1A') and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase II results in Alzheimer's disease and will be advanced through partnerships</p>
 <p>phost'in therapeutics www.phostin.com</p>	<p>PHOST'IN THERAPEUTICS</p> <p>PHOST'IN THERAPEUTICS develops First-In-Class N-glycosylation inhibitors for treatment of solid cancers. Our candidate PhOx430 is currently applying for Clinical Trial Authorization for a Phase I/Ib (cohorts) in Europe, after completing regulatory package in 2021. Phost'in begins preparing a Series-B for 2023, for a Phase(s) II / new indications and new generations.</p>

 www.seabelife.com	<p>SEABELIFE</p> <p>SEABELIFE is a biotechnology company specialized in the development of drug candidates that block cellular necrosis in order to protect or regenerate organs affected by severe pathologies. The company primarily targets acute pathologies of the liver and kidneys, whilst leading other research activities in ocular and degenerative conditions. SeaBeLife's technology centers around a portfolio of more than 45 biologically-active relevant molecules, which have the unique characteristic of inhibiting two forms of regulated and programmed cell death – necroptosis and ferroptosis.</p>
 www.sensome.com	<p>SENSOME</p> <p>SENSOME, a clinical-stage start-up founded in 2014, has developed a revolutionary sensor technology that turns invasive medical devices into connected healthcare devices. The company's patented sensing technology combines the world's smallest impedance-based micro-sensor with machine learning algorithms to instantly identify biological tissues with unequalled predictive reliability. Sensome's first product the Clotild® Smart Guidewire System is a connected neurovascular guidewire to categorize blood clots during the endovascular treatment of acute ischemic stroke (AIS), a billion dollar market opportunity.</p>
 www.theraclion.com	<p>THERACLION'S</p> <p>Theraclion's ambition is to make unnecessary surgery a thing of the past and non-invasive High Intensity Focused Ultrasound (HIFU) a standard of care. Theraclion has revolutionized HIFU – until then only applied to deep-seated targets such as for example prostate cancer and myoma – by developing a solution for non-deep targets.</p>
 www.transgene.fr	<p>TRANSGENE</p> <p>TRANSGENE (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).</p>

 www.tribun.health	<p>TRIBVN</p> <p>We envision a world where cancer is no longer a deadly disease. TRIBVN HEALTH provides the only enterprise AI-powered digital pathology platform. With such a digital solution, clinicians access current and historical images—from anywhere and at any time. Second opinions are just a mouse click away. And with the power of AI, elements of image analyses can be automated to get the job done faster and with higher confidence.</p>
 www.uromems.com	<p>UROMEMS</p> <p>UROMEMS aims to restore the quality of life, dignity and self-esteem of millions of men and women worldwide suffering from untreated chronic conditions. The first challenge for the company will be applying robotic methods and smart systems for treating urinary incontinence: designed by urologists and collaborating scientists and engineers, the UroMems first product will present a new standard of care combining safety, efficacy, durability and ergonomics fitting any individual's lifestyle and anatomy.</p>
 www.vect-horus.com	<p>VECT-HORUS</p> <p>VECT-HORUS designs and develops vectors that facilitate targeting and delivery of biotherapeutic or imaging agents to organs, including the brain and tumors, with the ambition to treat or diagnose CNS diseases, cancers or genetic disorders. The VECTrans® technology enables the development of vectorized therapeutic or imaging agents that specifically target cell-surface receptors, allowing them to cross physiological barriers, first and foremost the blood-brain-barrier, to improve their distribution profile.</p>
 www.withings.com	<p>WITHINGS</p> <p>Founded by visionary innovators Eric Carreel and Cédric Hutchings in 2008, the Withings team of engineers, doctors, and health professionals invent the world's most efficient devices to help track and analyze anyone's vitals. The ecosystem range includes award-winning products across the health spectrum, including hybrid smartwatches and health trackers (Move, Move ECG, Steel, Steel HR, Steel HR Sport, Pulse HR), connected scales (Body Cardio, Body+, Body), blood pressure monitors (BPM Core and BPM Connect), and an advanced sleep system (Sleep Analyzer). Every piece of collected data comes to life in the free Health Mate app, where users can find coaching, motivation, and valuable insights to share with their doctors and shape key aspects of their health.</p>



French Healthcare is an innovative public-private initiative aimed at bringing together all the players in the French healthcare ecosystem (businesses, researchers, healthcare professionals, key public stakeholders, etc.) to jointly promote their activities, expertise, technologies and innovations internationally. It helps to trigger a collective approach dynamic that stimulates international cooperation in the field of health and to promote the vision that health, a vector of social progress, must be improved for everyone everywhere in the world. This initiative is supported by the Ministry for Europe and Foreign Affairs, the French Healthcare Association and Business France.



Choose France is a registered trademark of the French government that promotes France's economic attractiveness internationally.


Produced by Business France





Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France's companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program.

Business France has 1,500 personnel, both in France and in 55 countries throughout the world, who work with a network of partners. Since January 2019, as part of the reform of the state support system for exports, Business France has given private partners responsibility for supporting French SMEs and mid-size companies in the following markets: Belgium, Hungary, Morocco, Norway, the Philippines and Singapore.

[FrenchHealthcare.fr](https://www.FrenchHealthcare.fr)

 [@FrHealthCare_EN](https://twitter.com/FrHealthCare_EN)

 [French Healthcare](https://www.linkedin.com/company/FrenchHealthcare)

 [French Healthcare x Business france](https://www.youtube.com/channel/UC...)